KR930012020A - 뇌순환의 자기조절을 안정화시키기 위한 크산틴 유도체의 용도 - Google Patents
뇌순환의 자기조절을 안정화시키기 위한 크산틴 유도체의 용도 Download PDFInfo
- Publication number
- KR930012020A KR930012020A KR1019920023765A KR920023765A KR930012020A KR 930012020 A KR930012020 A KR 930012020A KR 1019920023765 A KR1019920023765 A KR 1019920023765A KR 920023765 A KR920023765 A KR 920023765A KR 930012020 A KR930012020 A KR 930012020A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- alkyl
- straight
- oxoalkyl
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004556 brain Anatomy 0.000 title claims abstract 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims abstract 8
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 25
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000005188 oxoalkyl group Chemical group 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 3
- 230000006641 stabilisation Effects 0.000 claims abstract 3
- 238000011105 stabilization Methods 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 230000002685 pulmonary effect Effects 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000075 primary alcohol group Chemical group 0.000 claims 2
- 150000003333 secondary alcohols Chemical class 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 150000003509 tertiary alcohols Chemical class 0.000 claims 2
- 235000008694 Humulus lupulus Nutrition 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4140805 | 1991-12-11 | ||
| DEP4140805.5 | 1991-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930012020A true KR930012020A (ko) | 1993-07-20 |
Family
ID=6446782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920023765A Withdrawn KR930012020A (ko) | 1991-12-11 | 1992-12-10 | 뇌순환의 자기조절을 안정화시키기 위한 크산틴 유도체의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0547508A1 (https=) |
| JP (1) | JPH05246850A (https=) |
| KR (1) | KR930012020A (https=) |
| AU (1) | AU3000292A (https=) |
| CA (1) | CA2085046A1 (https=) |
| HU (2) | HUT62799A (https=) |
| IL (1) | IL104037A0 (https=) |
| MX (1) | MX9207156A (https=) |
| TW (1) | TW209834B (https=) |
| ZA (1) | ZA929566B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856330A (en) * | 1996-07-31 | 1999-01-05 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin |
| US5981536A (en) * | 1996-07-31 | 1999-11-09 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the modulation of apoptosis |
| WO2025046257A1 (en) * | 2023-08-25 | 2025-03-06 | Hikal Limited | A substantially pure propentofylline and preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH062675B2 (ja) * | 1985-04-05 | 1994-01-12 | ヘキストジヤパン株式会社 | 記憶障害治療剤 |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| DE3942871A1 (de) * | 1989-12-23 | 1991-06-27 | Hoechst Ag | R-(-)-1-(5-hydroxyhexyl)-3-methyl-7-propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel |
-
1992
- 1992-07-25 TW TW081105887A patent/TW209834B/zh active
- 1992-12-09 IL IL104037A patent/IL104037A0/xx unknown
- 1992-12-10 JP JP4330129A patent/JPH05246850A/ja active Pending
- 1992-12-10 EP EP92121076A patent/EP0547508A1/de not_active Withdrawn
- 1992-12-10 AU AU30002/92A patent/AU3000292A/en not_active Abandoned
- 1992-12-10 CA CA002085046A patent/CA2085046A1/en not_active Abandoned
- 1992-12-10 ZA ZA929566A patent/ZA929566B/xx unknown
- 1992-12-10 HU HU9203909A patent/HUT62799A/hu unknown
- 1992-12-10 HU HU9203909A patent/HU9203909D0/hu unknown
- 1992-12-10 KR KR1019920023765A patent/KR930012020A/ko not_active Withdrawn
- 1992-12-10 MX MX9207156A patent/MX9207156A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0547508A1 (de) | 1993-06-23 |
| JPH05246850A (ja) | 1993-09-24 |
| CA2085046A1 (en) | 1993-06-12 |
| TW209834B (https=) | 1993-07-21 |
| HUT62799A (en) | 1993-06-28 |
| HU9203909D0 (en) | 1993-03-29 |
| AU3000292A (en) | 1993-06-17 |
| ZA929566B (en) | 1993-06-16 |
| IL104037A0 (en) | 1993-05-13 |
| MX9207156A (es) | 1993-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU97115713A (ru) | Соединения, содержащие бензопиран и способ их применения | |
| JPH01294623A (ja) | ４‐置換イミダゾール誘導体を有効成分とする手術に際して使用する薬剤 | |
| DE69109631D1 (de) | 2-Substituierte Adenosinderivate und pharmazeutische Zusammensetzungen zur Verwendung gegen Infektionskrankheiten. | |
| MY102565A (en) | Novel derivatives of guanine | |
| KR930006036A (ko) | 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체 | |
| KR890011592A (ko) | 기관내 허혈병의 치료용 조성물 | |
| Kerr et al. | Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug | |
| CA2176298C (en) | A single high dose fluoroquinolone treatment | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| DORNETTE et al. | Clinical experiences with 1, 1, 1 trichloroethane: a preliminary report of 50 anesthetic administrations | |
| KR910000734A (ko) | 네플라노신 유도체 | |
| US3922340A (en) | Pharmaceutical compositions for treating lung diseases | |
| KR950703949A (ko) | 히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds) | |
| KR930001911A (ko) | 두개-뇌 외상후의 이차 신경 세포 손상 및 기능 장애를 치료하기 위한 크산틴 유도체의 용도 | |
| KR930012020A (ko) | 뇌순환의 자기조절을 안정화시키기 위한 크산틴 유도체의 용도 | |
| KR890003384A (ko) | B형 간염의 항 비루스 치료방법 및 조성물 | |
| JPS60202822A (ja) | 抗ウイルス薬 | |
| US3051625A (en) | Dithiocarbamate tumor-inhibitory process | |
| DK149810C (da) | Analogifremgangsmaade til fremstilling af basisk substituerede 3-oxopyridaziner og deres fysiologisk acceptable syreadditionssalte | |
| KR860003018A (ko) | 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법 | |
| Marshall et al. | Interaction between negative inotropic effects of halothane and nifedipine in the isolated rat heart | |
| ATE18761T1 (de) | Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen. | |
| KR920005719A (ko) | 라브단 및 이의 제조방법 | |
| KR870007098A (ko) | 플루오르화 디아미노알킨유도체 및 이의 제조방법 | |
| Julihn et al. | Electrographic studies of isoflurane (Forane) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19921210 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |